Stockreport

Werewolf Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update

Werewolf Therapeutics, Inc.  (HOWL) 
PDF – Update on WTX-124 Phase 1/1b clinical trial interim data and End of Phase 1 meeting with the U.S. Food & Drug Administration (FDA) is expected to be provided later in [Read more]